Leerink Partnrs Weighs in on Crinetics Pharmaceuticals, Inc.’s Q3 2025 Earnings (NASDAQ:CRNX)

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) – Analysts at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of Crinetics Pharmaceuticals in a report issued on Thursday, August 8th. Leerink Partnrs analyst J. Schwartz anticipates that the company will earn ($1.01) per share for the quarter. The consensus estimate for Crinetics Pharmaceuticals’ current full-year earnings is ($3.54) per share. Leerink Partnrs also issued estimates for Crinetics Pharmaceuticals’ Q4 2025 earnings at ($1.02) EPS.

A number of other equities analysts also recently issued reports on the company. Morgan Stanley raised their price objective on Crinetics Pharmaceuticals from $50.00 to $70.00 and gave the stock an “overweight” rating in a research report on Thursday, May 23rd. Robert W. Baird lifted their target price on Crinetics Pharmaceuticals from $52.00 to $62.00 and gave the stock an “outperform” rating in a report on Thursday, May 23rd. Piper Sandler reiterated an “overweight” rating and issued a $97.00 target price on shares of Crinetics Pharmaceuticals in a report on Tuesday, July 2nd. HC Wainwright lifted their target price on Crinetics Pharmaceuticals from $60.00 to $69.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $80.00 target price on shares of Crinetics Pharmaceuticals in a report on Tuesday, June 4th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, Crinetics Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $64.75.

Crinetics Pharmaceuticals Trading Up 1.5 %

Shares of CRNX stock opened at $50.33 on Monday. The business’s 50-day moving average price is $48.64 and its 200-day moving average price is $45.32. Crinetics Pharmaceuticals has a 12 month low of $15.76 and a 12 month high of $55.78. The firm has a market capitalization of $3.97 billion, a price-to-earnings ratio of -13.31 and a beta of 0.68.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.08). The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.47 million. During the same quarter in the previous year, the business earned ($0.94) earnings per share. The firm’s quarterly revenue was down 59.6% compared to the same quarter last year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CRNX. Comerica Bank bought a new stake in shares of Crinetics Pharmaceuticals in the first quarter valued at $33,000. Quarry LP bought a new stake in shares of Crinetics Pharmaceuticals in the fourth quarter valued at $36,000. Quest Partners LLC bought a new stake in shares of Crinetics Pharmaceuticals in the second quarter valued at $42,000. AJOVista LLC bought a new stake in shares of Crinetics Pharmaceuticals in the fourth quarter valued at $58,000. Finally, Amalgamated Bank raised its stake in shares of Crinetics Pharmaceuticals by 20.8% in the second quarter. Amalgamated Bank now owns 2,692 shares of the company’s stock valued at $121,000 after buying an additional 464 shares during the period. Hedge funds and other institutional investors own 98.51% of the company’s stock.

Insider Activity at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, CFO Marc Wilson sold 32,129 shares of the business’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $43.61, for a total value of $1,401,145.69. Following the transaction, the chief financial officer now owns 111,092 shares of the company’s stock, valued at $4,844,722.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Crinetics Pharmaceuticals news, insider Dana Pizzuti sold 9,500 shares of the business’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $45.73, for a total value of $434,435.00. Following the transaction, the insider now owns 27,786 shares of the company’s stock, valued at $1,270,653.78. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Marc Wilson sold 32,129 shares of the business’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $43.61, for a total value of $1,401,145.69. Following the completion of the transaction, the chief financial officer now directly owns 111,092 shares in the company, valued at approximately $4,844,722.12. The disclosure for this sale can be found here. Insiders have sold a total of 170,016 shares of company stock valued at $8,320,842 over the last 90 days. Insiders own 6.00% of the company’s stock.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.